Nimish Dalal
About Nimish Dalal
Nimish Dalal is the Director of Vector and Gene Delivery - MS&T, Cell Therapy Development Operations at Bristol Myers Squibb in Summit, New Jersey, United States.
Title
Nimish Dalal is the Director of Vector and Gene Delivery - MS&T, Cell Therapy Development Operations at Bristol Myers Squibb. He operates out of Summit, New Jersey, United States.
Company
Nimish Dalal has been a part of Bristol Myers Squibb for several years, taking on various roles and increasing responsibilities. He has played a significant role in the Cell Therapy Development Operations, particularly in vector and gene delivery. His current position involves managing a global team tasked with supporting viral vector manufacturing for CAR-T drug products.
Previous Positions at Bristol Myers Squibb
Nimish Dalal has held multiple positions at Bristol Myers Squibb. From 2018 to 2020, he worked as an Associate Director - Manufacturing Technology in East Syracuse, NY. Prior to that, he served as the Associate Director - Technical Product Team Lead from 2016 to 2018. Between 2014 and 2016, he was the Senior Engineer I / Senior Engineer II - Drug Substance Process Lifecycle Champion. From 2011 to 2014, he was involved in Manufacturing Sciences & Technology - Upstream as an Engineer II / Senior Engineer I. Nimish began his career at Bristol Myers Squibb as an Engineer / Project Engineer - Process Development - Upstream from 2004 to 2011.
Educational Background
Nimish Dalal holds a Ph.D. in Chemical Engineering from the University of Maryland, completed between 1998 to 2001. He also earned an M.S. in Chemical Engineering from the same institution from 1995 to 1998. Prior to that, he achieved his B.S. in Chemical Engineering from Penn State University, where he studied from 1990 to 1994.
Role and Responsibilities
In his capacity as Director at Bristol Myers Squibb, Nimish Dalal is responsible for leading a global team of process engineers and scientists. His team focuses on viral vector manufacturing, particularly for CAR-T drugs. He manages technology transfers and pre-pivotal technical development activities at internal and external sites. He oversees life cycle activities across both adherent and suspension technology platforms, and provides crucial commercial manufacturing support for viral vectors. Additionally, he supports global health authority submissions and inspections related to viral vector manufacturing processes.